Trials / Completed
CompletedNCT00234065
Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)
Post-marketing Study of Cilostazol: Study to Confirm Efficacy in Preventing Recurrent Cerebral Infarction in Comparison With Aspirin
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 2,800 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the efficacy of cilostazol in preventing recurrence of cerebral infarction and the safety of long-term administration of the drug (100 mg, twice daily) in patients with cerebral infarction (excluding cardiogenic cerebral embolism) in a multi-center, double-blind, parallel-group comparison with aspirin (81 mg, once daily).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cilostazol | oral tablet, 100 mg twice a day and placebo of aspirin once a day, 1 to 5years |
| DRUG | Aspirin | oral tablet, placebo of cilostazol twice a day and 81 mg once a day, 1 to 5 years |
Timeline
- Start date
- 2003-12-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2005-10-06
- Last updated
- 2011-06-10
- Results posted
- 2011-05-13
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00234065. Inclusion in this directory is not an endorsement.